S.K. Joshi
AbbVie
5 Papers
35 Citations
S.K. Joshi is an academic researcher from AbbVie. The author has contributed to research in topics: Neuropathic pain & Nociception. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states.
S.K. Joshi,Joseph P. Mikusa,Gricelda Hernandez,Scott J. Baker,Char-Chang Shieh,Torben R. Neelands,Xu-Feng Zhang,Wende Niforatos,Karen Kage,Ping Han,Douglas S. Krafte,Connie R. Faltynek,James P. Sullivan,Michael F. Jarvis,Prisca Honore +14 more
TL;DR: A greater involvement of Nav 1.8 in frank nerve injury and inflammatory pain as compared to acute, post‐operative or chemotherapy‐induced neuropathic pain states is demonstrated.
193
Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain.
TL;DR: It is demonstrated that morphine and ABT-594 produce antinociception in CP-cystitis by a predominantly supraspinal site of action, and that mechanisms producing robust centrally-mediated antinOCiception could be beneficial in cystitis pain.
35
Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
Eric A. Voight,Arthur Gomtsyan,Jerome F. Daanen,Richard J. Perner,Robert G. Schmidt,Erol K. Bayburt,Stanley Didomenico,Heath A. McDonald,Pamela S. Puttfarcken,Jun Chen,Torben R. Neelands,Bruce R. Bianchi,Ping Han,Regina M. Reilly,Pamela H. Franklin,Jason A. Segreti,Richard A. Nelson,Zhi Su,Andrew J. King,James S. Polakowski,Scott J. Baker,Donna Gauvin,LaGeisha R. Lewis,Joseph P. Mikusa,S.K. Joshi,Connie R. Faltynek,Philip R. Kym,Michael E. Kort +27 more
TL;DR: The synthesis and characterization of a series of selective, orally bioavailable TRPV1 antagonists led to the eventual identification of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea, an analogue that possesses excellent pharmacological selectivity, has a favorable pharmacokinetic profile, and demonstrates good efficacy against osteoarthritis pain in rodents
Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists
Arthur Gomtsyan,Robert G. Schmidt,Erol K. Bayburt,Gregory A. Gfesser,Eric A. Voight,Jerome F. Daanen,Diana Schmidt,Marlon D. Cowart,Huaqing Liu,Robert J. Altenbach,Michael E. Kort,Bruce Clapham,Phil B. Cox,Anurupa Shrestha,Rodger F. Henry,David N. Whittern,Regina M. Reilly,Pamela S. Puttfarcken,Jill-Desiree Brederson,Ping Song,Bin Li,Susan M. Huang,Heath A. McDonald,Torben R. Neelands,Steve McGaraughty,Donna Gauvin,S.K. Joshi,Patricia N. Banfor,Jason A. Segreti,Mohamad Shebley,Connie R. Faltynek,Michael J. Dart,Philip R. Kym +32 more
TL;DR: Systematic optimization of pharmacological, physicochemical, and ADME properties of original lead 5a resulted in identification of a novel and selective TRPV3 antagonist 74a, which demonstrated a favorable preclinical profile in two different models of neuropathic pain as well as in a reserpine model of central pain.
Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
S.K. Joshi,Prisca Honore,Gricelda Hernandez,Robert G. Schmidt,Arthur Gomtsyan,Marc J. C. Scanio,Michael E. Kort,Michael F. Jarvis +7 more
TL;DR: Effects of coadministration of TRPV1 antagonists and A-803467, a Nav1.8 blocker, were investigated in preclinical rodent models of neuropathic and inflammatory pain and produced an additive interaction in attenuating CFA-induced thermal hyperalgesia.